TKT and neoplasm: Preclinical models demonstrated that, after Ad-TK + Ad-Flt3L treatment, DC are activated by damage-associated molecular pattern molecules as HMGB1 and after uptake of tumor antigens from dying cells they prime a systemic immune response [162].